- Malaysia Airlines pilots sometimes left cockpit door unlocked: U.S. businessman
- PHILLIPS: The benefits of defying ‘common wisdom’
- Judge strikes down Arkansas abortion law — nation’s toughest — as unconstitutional
- Court: Tenn. must recognize 3 same-sex marriages
- Russia claims to have downed U.S. drone over Crimea region; Pentagon denies
- John Daly shoots 90 at PGA Tour event: ‘I’m falling apart’
- Police: Man arrested in West Virginia may be linked to Alexandria killings
- Smile: Equipping cops with body-mounted cameras gains steam in Calif., N.Y.
- Obama to sign bill cutting taxpayer money for party conventions
- Half of Americans worried about second Cold War: poll
Lilly Alzheimer’s drug trial yields promising sign
INDIANAPOLIS (AP) - A possible Alzheimer’s disease treatment from drugmaker Eli Lilly showed some promise in late-stage research, even though the drug failed to slow a form of mental decline in two separate studies of patients with the mind-robbing condition.
Shares of the Lilly soared Friday in morning trading after the Indianapolis company announced what could be a step toward a long-awaited breakthrough in the fight against a disease that has no cure and ultimately proves fatal. But Lilly officials cautioned that it’s important not to overreact to their initial results.
Lilly said Friday its treatment, solanezumab, failed to slow cognitive decline, which involves a person’s memory, in two late-stage studies of about 1,000 patients each. But when data from the trials was combined, scientists saw a statistically significant slowing of the rate of cognitive decline in the bigger population.
They also saw a statistically significant result when they examined a subgroup of patients with mild cases of Alzheimer’s disease. The studies focused on patients with mild to moderate Alzheimer’s cases.
Lilly shares climbed $2.46, or nearly 6 percent, to $44.90 in morning trading..
The studies fell short of their main goals, and that means the drug “isn’t going to the (Food and Drug Administration) tomorrow to be approved for sale,” said William H Thies, chief medical and scientific officer for the Alzheimer's Association, which was not involved in Lilly’s research. Still, he said the statistical significance of the combined results is important.
“If that can be replicated, that is a major finding,” he said. “It’s the first time we’ve been able to change the course of Alzheimer’s disease or any part of Alzheimer’s disease in people.”
Lilly said it will discuss the results with regulators and plan the next steps. Full results from the studies will be presented at two scientific conferences in October.
About 35 million people worldwide have dementia, a term for brain disorders that affect memory, judgment and other mental functions. Alzheimer’s is the most common type. In the United States, more than 5 million people have Alzheimer’s, which is the country’s sixth-leading cause of death.
Many Alzheimer’s patients typically live four to eight years after diagnosis, as the disease gradually erodes their memory and ability to think or perform simple tasks. Current Alzheimer’s treatments only temporarily ease symptoms such as memory loss, confusion and agitation. They don’t slow, stop or reverse mental decline.
Drugmakers have tried and failed for years to develop successful treatments for the disease, and patients and doctors are anxious for any signs of promise. Analysts have said an approved treatment that slows the disease’s progression could be worth billions of dollars in sales.
Earlier this month, Pfizer Inc. and Johnson & Johnson said they would end development of an intravenous version of their potential Alzheimer’s treatment, bapineuzumab, after two late-stage studies showed it worked no better than a placebo in patients with mild-to-moderate cases.
Lilly officials cautioned Friday that their study did not show that solanezumab slowed the progression of Alzheimer’s. It showed signs of slowing cognitive decline, one of many ways the disease impacts a person’s mind. Even so, they were encouraged.
Solanezumab binds to beta-amyloid protein, which scientists believe is a key component to sticky plaque that basically gums up the brain of a patient with Alzheimer’s disease. The drug is designed to bind to the protein and help the body remove it from the brain before it can form that plaque. Lilly said that while the individual trials missed their main goals, the combined results showed there may be some validity to this approach.
“We really think this idea of attacking amyloid plaques is a valid hypothesis, that’s important news,” said Dave Ricks, president of Lilly Bio-Medicines.
TWT Video Picks
By David A. Clarke Jr.
Blame Washington's intelligence failure, not lack of police
- CURL: We completely overhauled American health care to insure 4.2 million people?
- California gun store owner refuses to hand over customer list
- Bill Maher: God a 'psychotic mass murderer' who 'drowns babies'
- Firefighters discover church's Bible in Harlem rubble following gas explosion
- Crimea votes in favor of secession, U.S. rejects
- College group's diversity event canceled after excluding white people
- Trust me: Obama promises new overtime rules will be 'easier for everyone'
- McCaul offers scenario where missing Malaysian jet lands in hostile country to be use as missile
- EXCLUSIVE: FBI blocked in corruption probe involving Sens. Reid, Lee
- U.S. pilot scares off Iranians with 'Top Gun'-worthy stunt: 'You really ought to go home'
Chaos as Manhattan building explodes
Pope Francis meets his 'mini-me'
Celebrity deaths in 2014